Singlera Genomics Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Singlera Genomics Inc
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.
As the traditional lines between therapeutics and diagnostics become increasingly blurred, genomic testing is growing apace in China, boosted by the country’s national push into precision medicine. Deals and alliances are coming thick and fast as companies jostle for a slice of the growing pie.
Another slow month for VC financing deals means total deal value for 2016 to date is now lagging behind that for the same period last year.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools